IBB Stock UPDATES Nasdaq Biotechnology Ishares (IBB) 266.09 09/15/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 266.09 $IBB

iShares Nasdaq Biotechnology Index Falls 1.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 3:57PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $263.64 to a high of $268.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $268.24 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

3 Reasons Actavis plc Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 15, 10:50AM CDT
Healthcare and biotechnology stocks have put on another amazing show this year, with the closely watched  iShares Nasdaq Biotechnology Index   pushing higher by nearly 19% so far. And certain subsectors, including generic and specialty...

WIT, IBB, EROC, MPX, SEP, TUZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Wipro Ltd (NYSE:WIT), Ishares Nasdaq Biotechnology (NASDAQ:IBB), EAGLE ROCK ENERGY PARTNERS (NASDAQ:EROC), Marine Products Corp (NYSE:MPX), Spectra Energy Partners LP (NYSE:SEP), PimCo 1 3 Year Us Treasury Index Fund (NYSE:TUZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

After Yesterday's Rally of 1.85% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 10, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 1.85%
Comtex SmarTrend(R) - Wed Sep 10, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 1.65% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Economic Recovery Doesn't Satisfy Fed as Stocks Soar Higher
at The Street - Thu Aug 21, 10:14AM CDT
Low inflation and slack in the labor market has kept policymakers dovish, leading to strength in U.S. equities and in high-beta sectors.

Nasdaq Composite: What Are You Buying That's Driving New Highs? - Real Time Insight
Zacks Equity Research - ZACKS - Mon Aug 18, 1:04PM CDT
It's not just the big caps attracting all the money

Eased Geopolitical Tensions Have Little Effect on Interest Rates
at The Street - Fri Aug 15, 11:16AM CDT
It seems that no matter what, investors just want a reason to continue buying bonds and pressuring rates lower.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Palmer Holland Takes Natural Colors Across North America

Updated Category News Views 27

Natural food color sounds like a tidy little ingredient story until somebody tries to keep a blue beverage blue on a retail shelf. That is where Palmer Holland's new exclusive North American commercial arrangement with BOTANIKind gets interesting. This is not a flashy public-market transaction, and neither company has handed investors a revenue figure, volume target, or...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 47

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
M.O.L.I.F.E. Brings Community Inclusion Into Public View

Updated Category News Views 138

A food pantry can reveal more about inclusion than a polished mission statement ever will. M.O.L.I.F.E., Inc. is set to be featured in an educational segment of All Access with Andy Garcia, and the useful part of this story is not the celebrity-host packaging. It is the organization’s insistence that employment, independent living, day programming, residential support,...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 30

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 74

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 112

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 101

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading

Top 5 Most Recently Viewed Articles

Mobile Homes Market Grows to $16.62B by 2031

Updated Category News Views 24

Affordable Housing Fuels Mobile Homes Market When the traditional real estate market is out of reach, what's the average Joe supposed to do? Enter the mobile home market, which is expected to leap from $11.87 billion in 2026 to a hefty $16.62 billion by 2031. That's a compound annual growth rate (CAGR) of 6.96%—not too shabby for a sector often ignored by the mainstream...

Continue Reading
KinderCare Investors Face Legal Challenges Over IPO Misrepresentation

Updated Category News Views 213

Legal Action Against KinderCare Learning Companies A securities class action lawsuit has been initiated against KinderCare Learning Companies, Inc. (NYSE: KLC) and its executives. This lawsuit centers on allegations that the company misrepresented its activities and safety records during its Initial Public Offering (IPO) in October 2024. Investors who acquired KLC common...

Continue Reading
Intec Pharma Ltd's Stock Sees Decline: A Deeper Analysis

Updated Category News Views 204

Intec Pharma Ltd Faces a Rocky Road Intec Pharma Ltd (NASDAQ: INDP) is knee-deep in trouble, with its stock diving to a brutal 52-week low of $1.20. This stark drop of 56.12% over the past year paints a dismal picture for investors scoping out this biotech player. It’s no surprise that all eyes are on INDP as it struggles to navigate these choppy waters and rebuild its...

Continue Reading
Sol Rei Wine Shines at San Francisco Wine Competition

Updated Category News Views 190

Celebrating Excellence at the San Francisco Wine Competition In an impressive display of craftsmanship and quality, Sol Rei Wine has recently achieved remarkable accolades at the esteemed San Francisco Wine Competition. This boutique, women-owned wine brand has won both Double Gold and Gold medals for their exquisite offerings: the Sol Rei Syrah and the Sol Rei Private...

Continue Reading
Insight Molecular Diagnostics Gears Up for Exciting 2026 Launch

Updated Category News Views 260

Exciting Progress Ahead for Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is taking significant strides towards launching its innovative GraftAssureDx™ test in 2026. With anticipation building within the organization and among stakeholders, the company is preparing to submit its application for FDA approval by the year's end. This...

Continue Reading